Stoptions.aiStoptions.aiStoptions.aiStoptions.aiStoptions.ai
Powered by Amora Edge
How it worksResultsPricingMeet StoptieCompareBlog
Sign inStart free trial
Stoptions.ai
Powered by Amora Edge

Algorithmic scanning across the S&P 500 & Nasdaq 100. Stock & Options trade cards in your inbox by 9:35 AM ET every trading day.

Product
  • How it works
  • The Algorithm
  • Ticker Setups
  • Pricing
  • Morning Brief
  • Results
  • Compare tools
Account
  • Sign in
  • Start free trial
  • Give a gift
  • Dashboard
  • Settings
Company
  • About
  • Contact
  • Support
  • Blog
  • Sitemap
Legal
  • Terms of service
  • Privacy policy
  • Risk disclosure
  • Unsubscribe

© 2026 Stoptions.ai · All Rights Reserved

Not financial advice. Algo-generated setups are not personalised investment advice. Options trading involves significant risk of loss — past performance does not guarantee future results.

Chat with Stoptie
Stoptions.ai›Tickers›LNTH
Last updated: Mon May 11, 2026 · 9:31 AM ET
↻ Next update: Thu May 14, 2026 · 9:31 AM ET

LNTH Stock and Options Trade Setup — Lantheus Holdings, Inc.LNTH logo

Nasdaq · Nuclear Medicine & Radiopharmaceuticals · Moderate options liquidity · Mid cap · ~$4.0B

▲ Bullish setupPYLARIFY Market LeaderNuclear Medicine GrowthRadiopharmaceutical Therapy↑ Score +6 vs last update
74
Amora Edge Score
74
Top 25%
↑ +6 vs last update
Composite of EMA, RSI, RS vs SPY & volume · updated every 72h
67
LNTH Win Rate
67%
6.7 of 10 LNTH setups hit target
Tracks completed Stoptions setups on this ticker since Jan 2026
Why we cover LNTH

Lantheus is riding the most powerful structural growth wave in nuclear medicine since the FDG era — PSMA PET imaging for prostate cancer detection and staging. PYLARIFY's approval transformed the diagnostic standard of care for millions of men annually, and adoption curves in academic and community imaging centers are still in the early-middle innings nationally. The radiopharmaceutical therapy (RPT) market is the next chapter: as nuclear medicine expands from diagnostic to therapeutic (treating tumors with targeted radiation), Lantheus's imaging expertise provides a natural adjacency into therapeutic tracers. Pipeline assets in prostate therapy and neurological imaging provide multiple shots on goal. PYLARIFY revenue has consistently beaten analyst expectations since launch. The imaging supply chain — cyclotrons, radiopharmacies, specialized logistics — creates significant barriers to new entrants.

Score History & Signal Changelog

Preview data

This page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.

Score progression across 4 updates
Solid = composite · dashed = components
Signal changelog
DateUpdateScoreDeltaKey change
Apr 28#1 Created68—Page created. PYLARIFY volume +55% YoY. Community adoption inflecting.
May 1#2 Update70+2Prostate RPT pipeline advancing. Phase 2 data expected mid-2026.
May 7#3 Update72+2Q1 PYLARIFY revenue +40% YoY. Guidance raised again.
May 11#4 Current74+2New radiopharmacy capacity online. Supply constraint removed for growth.

Signal Breakdown

EMA Cross
Active
22/25
EMA trend bullish. PYLARIFY adoption curve driving consistent momentum.
RSI Zone
Active
19/25
RSI 64. Strong growth stock momentum. Not extended.
RS vs SPY
Active
18/25
LNTH significantly outperforming XBI and healthcare sector.
Volume Surge
Active
15/25
High-quality institutional accumulation on emerging sector leadership.

Today's Trade Card

Setup
LNTH $80 CALL
Expires Jun 20, 2026
Premium
$4.20
Target
+80% premium
Stop loss
-50% premium
Breakeven
$84.2
Win prob.
44%
Sizing: Risk ≤ 1% of account
Greeks
Delta
0.42
Theta
-0.15
IVR
36%
IVR class
Moderate
Trade card available on Pro & Elite
Or start free trial →

Options Profile

Avg IV (30d)
40%
IVR range (52-wk)
28–68%
Put/call ratio
0.55
Avg daily vol.
4.2K contracts
Open interest
52K contracts
Next earnings
Jul 31, 2026 (est.)

Risks & Fundamentals

Every setup carries risk. Here's what could move LNTH against you, plus the key stats that frame any position.

Beta
1.4
Market cap
~$4.0B
Risk level
Medium risk
Next earnings
Jul 31, 2026 (est.)
Key risks to monitor
  • 1.PYLARIFY faces competition from Novartis's LOCAMETZ in the PSMA PET market
  • 2.Nuclear medicine logistics are complex and require significant capital in radiopharmacy infrastructure
  • 3.Reimbursement coverage for PSMA PET is still building in some payer segments
These are real risks to the long thesis, not a recommendation to short. Stoptions setups are short-dated and stop-protected; size accordingly.

LNTH Options Setup — Frequently Asked Questions

Is LNTH a good options trade today?+

Lantheus Holdings, Inc. (LNTH) currently has an Amora Edge Score of 74/100, ranking it top 25%. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.

What is LNTH's win rate on Stoptions.ai setups?+

LNTH's historical win rate on closed Stoptions setups is 67%. Win rate is calculated as the percentage of past LNTH trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.

What strike and expiry does Stoptions.ai suggest for LNTH?+

The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.

How often is the LNTH setup updated?+

Every 72 hours we refresh LNTH's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If LNTH drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.

What does the Amora Edge Score measure for LNTH?+

The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to LNTH: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is LNTH outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. LNTH currently scores 74.

How does LNTH compare to other Nuclear Medicine & Radiopharmaceuticals setups?+

LNTH's sector rank and percentile against other Nuclear Medicine & Radiopharmaceuticals tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Nuclear Medicine & Radiopharmaceuticals Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.

Educational content only — not personalized investment advice. Options carry substantial risk.

The Weekly · Free

Get a Friday recap including setups like LNTH.

Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.

No spam. One email Friday afternoon. Unsubscribe in one click.

More from Stoptions.ai
← All tickersHow the algorithm worksMorning BriefResultsPricing